Skip to main content

Alzheimer's Disease TRAILBLAZER-ALZ 3

Status: Closed to Enrollment

Study Details

View study details on clinicaltrials.gov.

Locations

  • San Francisco

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.

Armen Moughamian
Armen Moughamian
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?